Logo image of IOBT

IO BIOTECH INC (IOBT) Stock Fundamental Analysis

USA - NASDAQ:IOBT - US4497781090 - Common Stock

1.58 USD
0 (0%)
Last: 9/25/2025, 8:00:02 PM
1.6 USD
+0.02 (+1.27%)
After Hours: 9/25/2025, 8:00:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to IOBT. IOBT was compared to 538 industry peers in the Biotechnology industry. IOBT has a bad profitability rating. Also its financial health evaluation is rather negative. IOBT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IOBT had negative earnings in the past year.
In the past year IOBT has reported a negative cash flow from operations.
In the past 5 years IOBT always reported negative net income.
In the past 5 years IOBT always reported negative operating cash flow.
IOBT Yearly Net Income VS EBIT VS OCF VS FCFIOBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -245.68%, IOBT is doing worse than 92.01% of the companies in the same industry.
IOBT's Return On Equity of -6531.78% is on the low side compared to the rest of the industry. IOBT is outperformed by 84.01% of its industry peers.
Industry RankSector Rank
ROA -245.68%
ROE -6531.78%
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IOBT Yearly ROA, ROE, ROICIOBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IOBT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOBT Yearly Profit, Operating, Gross MarginsIOBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for IOBT remains at a similar level compared to 1 year ago.
Compared to 5 years ago, IOBT has more shares outstanding
There is no outstanding debt for IOBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IOBT Yearly Shares OutstandingIOBT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
IOBT Yearly Total Debt VS Total AssetsIOBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -19.15, we must say that IOBT is in the distress zone and has some risk of bankruptcy.
IOBT has a worse Altman-Z score (-19.15) than 84.01% of its industry peers.
A Debt/Equity ratio of 4.22 is on the high side and indicates that IOBT has dependencies on debt financing.
IOBT's Debt to Equity ratio of 4.22 is on the low side compared to the rest of the industry. IOBT is outperformed by 81.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.22
Debt/FCF N/A
Altman-Z -19.15
ROIC/WACCN/A
WACCN/A
IOBT Yearly LT Debt VS Equity VS FCFIOBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

IOBT has a Current Ratio of 1.96. This is a normal value and indicates that IOBT is financially healthy and should not expect problems in meeting its short term obligations.
IOBT has a Current ratio of 1.96. This is in the lower half of the industry: IOBT underperforms 75.84% of its industry peers.
IOBT has a Quick Ratio of 1.96. This is a normal value and indicates that IOBT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.96, IOBT is doing worse than 73.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.96
IOBT Yearly Current Assets VS Current LiabilitesIOBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IOBT have decreased by -6.25% in the last year.
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.93% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.78%
EPS Next 2Y17.61%
EPS Next 3Y14.94%
EPS Next 5Y13.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IOBT Yearly Revenue VS EstimatesIOBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
IOBT Yearly EPS VS EstimatesIOBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOBT. In the last year negative earnings were reported.
Also next year IOBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOBT Price Earnings VS Forward Price EarningsIOBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOBT Per share dataIOBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as IOBT's earnings are expected to grow with 14.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.61%
EPS Next 3Y14.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IOBT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IO BIOTECH INC

NASDAQ:IOBT (9/25/2025, 8:00:02 PM)

After market: 1.6 +0.02 (+1.27%)

1.58

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners66.43%
Inst Owner Change-4.64%
Ins Owners0.36%
Ins Owner Change0.06%
Market Cap104.09M
Analysts78.33
Price Target8.16 (416.46%)
Short Float %1.87%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.95%
Min EPS beat(2)3.61%
Max EPS beat(2)12.28%
EPS beat(4)2
Avg EPS beat(4)-6.88%
Min EPS beat(4)-22.76%
Max EPS beat(4)12.28%
EPS beat(8)5
Avg EPS beat(8)0.99%
EPS beat(12)7
Avg EPS beat(12)1.47%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.79%
PT rev (3m)-15.79%
EPS NQ rev (1m)1.13%
EPS NQ rev (3m)1.41%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 65.38
P/tB 65.38
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.26
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -245.68%
ROE -6531.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 4.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.96
Altman-Z -19.15
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.9%
EPS Next Y35.78%
EPS Next 2Y17.61%
EPS Next 3Y14.94%
EPS Next 5Y13.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.82%
EBIT Next 3Y-6.22%
EBIT Next 5Y-3.31%
FCF growth 1Y-35.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.11%
OCF growth 3YN/A
OCF growth 5YN/A